Adapting test ordering to novel tick-borne disease rise

It’s hard to make a diagnosis based on a one-time serologic test, Dr. Theel says. “For it to be a significant result, we like to see seroconversion”—negative at time point A and positive when retested at time point B, usually two weeks later. “That is definitive evidence of recent infection. But that’s not helpful in acute settings for patient care. That’s why we recommend molecular testing up front.”

An algorithmic approach like the one developed at Mayo is important for diagnosing tick-borne diseases now, she says. “Pathologists, microbiologists, and laboratories need to work with our patient-facing providers to guide them on what tests they should be ordering,” Dr. Pritt says. “That’s a really important role that laboratory leadership plays.”

The precise cause of the increasing diversity of tick-borne infections is unknown. But several studies suggest that less severe winters in cooler areas of the country such as the Northeast are allowing more larval ticks to survive the winter and helping increase the rate of not only Lyme but also pathogens like Babesia, Anaplasma, and Powassan virus, says Marc R. Couturier, PhD, medical director for infectious disease testing at ARUP Laboratories. He believes the emergence or detection of new species of tick-borne diseases is a side effect of that phenomenon.

“We’ve known about diseases like anaplasmosis and ehrlichiosis for decades, and we’ve seen them in serological testing. But we’re seeing newly emergent pathogens like Heartland virus and Bourbon virus,” he says. “Are those newly existing? Probably not. It’s probably that they were very rare viruses in the tick population, but the number of ticks is becoming larger and larger, so that low-incidence virus is more statistically likely to get exposed to a human.”

The vast majority of testing for tick-borne diseases is conducted by Quest, LabCorp, Mayo Medical Laboratories, and ARUP Laboratories, Dr. Couturier says. However, most other clinical labs are capable of doing the testing with ELISAs or direct fluorescent antibody testing. “These are methods we’ve used for decades. But one of the challenges for smaller labs to do the testing is the seasonality of it.”

“If they’re going to offer the testing, they get slammed during the season and then get almost no orders in the off-season. It can be difficult for a smaller lab to work with that type of ebb and flow, where they basically don’t run a test for months and then all of a sudden are overwhelmed by it,” Dr. Couturier says. “I think that’s why a lot of people continue to send tick-borne disease testing to reference labs. Even in the winter, our volumes don’t die. There’s enough trickling in from enough labs for us to keep the competency and quality assurance up.”

No single test can be used for tick-borne diseases in all situations, he says. “That’s one of the major nuances of tick-borne disease testing. We have an arsenal of weapons available and you need the right test for the right phase of the disease. If the patient has been sick for a while and they are convalescing, then PCR may not be valuable; you may need to do serology on that patient. And vice versa—if that patient is acutely ill, serology would be inappropriate because there’s a good chance they don’t have antibodies yet.”

While molecular testing continues to be laboratory-developed testing—“and not everyone has the bandwidth, capabilities, and patience to do that”—several manufacturers are pursuing FDA clearance for molecular tests, he says. ARUP recently studied the PCR multiplex assay of one such company, ChromaCode, which is hoping to secure FDA clearance and have its assay available on a few different platforms in about a year (Shakir S, et al. J Clin Microbiol. 2020;58[3]:e01655-19). Other companies have had singleplex testing for Babesia on the market for a couple of years, Dr. Couturier adds, but he is not sure how practical it is. “Where Babesia is endemic, you want to know if there is Anaplasma as well. So being able to have multiplexing will be important.”

Multiplexing has the potential, however, to throw too many targets at a patient, not all relevant, he cautions. “So you have a patient in Northern Maine who had an Ixodes tick and is at risk for four things. But the panel that’s on the market includes all the things that the Lone Star tick in the South can vector. If it’s on the panel, they are stuck with it”—along with the risk of false-positives. He hopes the companies can offer a way for laboratories to selectively mask targets they know are not appropriate to their region, or, in other cases where the source of infection is unknown, to decide to test everything.

Patients and sometimes clinicians may assume wrongly that PCR is going to be a better test than serology. “We’ve sung the praises of PCR for so long that it has created this impression that molecular always trumps serology; serology is archaic. But we have plenty of instances with viruses right now where that’s completely untrue. West Nile virus, Zika virus, dengue, and chikungunya are all emerging insect-vectored viruses that are still better diagnosed by serology than by PCR.” It’s not that the PCR is bad. “It’s that the pathogen either hides from our bodies so it’s difficult to sample, or the immune system is clearing the virus quickly. You try to do a PCR and the virus is already gone.”

“For the deer tick virus or Powassan virus, there is good data, especially because it has been increasing lately in prevalence, that PCR testing has a similar narrow window for detection,” Dr. Couturier says. On the other hand, with some of the bacteria and protozoa like Babesia, “when you’re testing the blood, it’s there for a decent amount of time and the nucleic acid can be detected even if the organism is dead. So we find that pathogens like Ehrlichia, Anaplasma, and Babesia, because they live in the blood as their normal cycle, are easy to detect by PCR.” ARUP has had a high rate of positives, upward of 20 percent at times, on those PCR tests, he says.

Lyme bacteria don’t hang around in blood. “They do much better in tissue,” he says. “So if you do a PCR using blood as a specimen, some data out there shows the test may be only 20 percent sensitive. It’s really poor. Whereas if you’re testing a lesion in the tissue where the tick bite was, or the synovial tissue in a joint infected by Lyme, the sensitivity is fantastic.”

The most common target of the multiplex tests he has seen in addition to the Lyme bacterium Borrelia burgdorferi are Anaplasma, Ehrlichia, and Babesia. “These are the core ones that everyone is going after. Some companies are looking at adding the relapsing fever spirochete, a different kind of Borrelia species, or Rickettsia rickettsii or Rocky Mountain spotted fever. We’ve not seen a lot of people pursuing the viruses yet, I think because the availability of positive specimens is scant.”

Comparatively speaking, the cost of serological tests has always been fairly stable and less than molecular testing across the board, Dr. Couturier notes. “While the costs of molecular testing have gone down, they are still a gap higher than serology because of the nature of the reagents. The pricing of PCR has come down over the last 10 years. And the more streamlined it becomes, the more companies can come out with these sample-to-answer tests, where a technician can take a sample, place it into a cartridge, then place the cartridge into an instrument. Now you’re cutting a lot of that labor expense. That’s ideally where we will get to.”

With the wider acquisition of easy-to-use broadly multiplex molecular testing, laboratories will be successful in detecting when specific ticks carry more than one tick-borne pathogen, Dr. Buchan says. “Casting that wider net to recognize those coinfections is important. Continued availability of reagents, be they commercial analyte-specific reagents, kits, or FDA-cleared tests, that can put these tests in the hands of local laboratories, will help increase testing for these non-Lyme pathogens. And that, in turn, should help diagnose a lot of these infections that are currently being misdiagnosed—or being missed altogether.”

Anne Paxton is a writer and attorney in Seattle.